Canada Dermatology prescription Market

A large database of syndicated market research
studies in pharmaceuticals and healthcare sector
on global, regional as well as country level. We
also provide customized research reports
tailormade to suit your needs.
Life Sciences Market
Research Reports you
can trust
www.insights10.com

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses.
Get Insights to take
informed Business
Decisions
www.insights10.com

Market Research Reports
across various domains of healthcare
Healthcare
Services
OTC &
Nutraceuticals
Pharmaceutical
(Diseases & Drugs)
Digital
Health
Medical
Devices

insights on which
our reports are
based
1
2
3
4
5
6
10
9
8
7
Market Overview
Growth Drivers and
Growth Restraints
Epidemiology &
Disease type
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policy and
Regulatory Landscape
Market Segmentation Reimbursement Scenario
Future Development Growth

Canada
Dermatology
Prescription
Market Analysis
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2021 – 2030)
www.insights10.com

This report presents a strategic analysis of the Canada Dermatology
Prescription market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market
value, dynamics, segmentation, characteristics, main players, trends and
insights, growth and demand drivers, challenges & future outlook, etc.
This is one of the most comprehensive reports about the Canada
Dermatology Prescription market, offering unmatched value, accuracy
and expert insights.

The report is prepared
using a proven
methodology and
insightful research.
Reliable
The data is prepared by
a team of highly qualified
& experienced research
analysts & vetted by our
local associates
Expert-verified
Allowing you to
confidently make smarter
business and strategic
decisions
Real
Covers everything you
would need to know
about the market
including market size,
competitive analysis &
much more.
Comprehensive
You do not have to be a
market expert to
understand what really is
happening on the market
and how it works.
Easy to read
What Kind of Data is Presented
in This Report?
This report presents data, which is:
www.insights10.com

9 Canada Dermatology Prescription Market I Confidential
Table of Contents
1. Methodology and Scope…………………………………………………………………….…………………………………………………..….08
1.1 Research Methodology
1.2 Analysis Methodology
1.3 Research Approach
1.4 Key benefits for stakeholders
2. Canada Dermatology Prescription Market Overview……………………………………………………………..…... …..…... …..…..... ..13
2.1 Introduction
2.2 Market size and forecast
3. Market Growth Drivers and Restraints …………………………………………………………………….…………………………………….16
3.1 Market Growth Drivers
3.1.1 Growing burden of skin diseases
3.1.2 Increase in the geriatric population
3.1.3 Increase in approval of dermatology drugs
3.1.4 Increase in public health care spending
3.2 Market Restraints
3.2.1 Availabilities of alternative treatments
3.2.2 Side effects associated with dermatology drugs
3.2.3 High cost of dermatology drugs and treatment

Table of Contents (continued)
4. Major Dermatological Diseases………………………………………………………………………………..…………………….…..…..23
4.1 Alopecia
4.2 Atopic Dermatitis
4.3 Psoriasis
4.4 Rosacea
4.5 Keratinocyte Carcinomas
4.6 Melanoma
4.7 Hyperhidrosis
5. Market Segmentation………………………………………………………………………………………………………..………………….26
5.1 By Disease Type
5.2 By Drug Class
5.3 By Route of Administration
5.4 By Distribution Channel
6. Market Share Analysis…………………………………………………………………………...…………..….......……………………………33
6.1 Major Products Market Share

Table of Contents (continued)
7. Competitive Landscape……………………………………………………………………………………………………….…………………...….36
7.1 Major Players & Products
7.2 Notable deals in the recent years in the Canada Dermatology prescription Market
8. Key Company Profiles (Company Overview, Product & Services, Strategies & Financials ). ………………………………………......38
8.1 GlaxoSmithKline
8.2 Johnson and Johnson
8.3 Merck
8.4 Pfizer
8.5 Novartis
8.6 Taro Pharmaceutical
8.7 Astra Zeneca
8.8 Bayer
8.9 Roche
9. Healthcare Policies and Regulatory Landscape………………………………….………………………………………………………………49
9.1 Policy changes and Reimbursement scenario
10. Factors Driving Future Growth……………………………………………………………………………………………………………….…….52

Report on Canada Dermatology Prescription Market
Methodology and Scope

Research Methodology
 Insights 10’s research methodology delves deep into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
 We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conducted extensive data mining, referring to verified data sources such as independent studies,
government and regulatory published material, technical journals, trade magazines, and paid data sources
 For forecasting, the following parameters were considered:
 Market drivers and restraints along with their current and expected impacts
 Technological scenario and expected developments
 End use industry trends and dynamics
 Trends in the consumer behavior
 Regulatory scenario and expected developments
 Current capacity and expected capacity additions up to 2030
 We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the
expected market growth rate
 We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
 All our estimates and forecasts were verified through exhaustive primary research with the Key Industry Participants (KIPs)

Analysis Methodology
• Final Market Size Break-up to Rest of
Segmentation i.e., Disease type, Drug Class,
Route of Administration, and Distribution
Channel
• Arriving at the Market Size of each Segment
• Data Validation with Primary Interviews
• Final Market Size
• Validation from Primary Interview
• Summation of Revenue Generated from
Companies to Arrive at Total Market Size
• Revenue Generated by Products offered by
Companies
Top Down Analysis
Bottom-up Analysis

Research Approach
The data presented is comprehensive, reliable, and the result of extensive research, both primary and secondary
Data Collection
• Primary Interviews (Industry
Participants, Outside experts)
• Secondary Data
Company Reports and Publications,
Government Data, Financial Reports of
Key Industry Players, Press Releases,
Scientific and Industry Publications and
Whitepapers
Market Data Analysis &
Statistical Model
• Market Trends
• Market Sizing and Analysis
• Data Triangulation & Validation
Market Trends such as Drivers,
Restraints, Opportunities, Challenges.
An intensive cross-verification and
validation process
Interpretation and
Presentation
• Analysis & Interpretation
• Insights
• Presentation & Reporting
The information gathered is then
analyzed and synthesized. The market
research report is presented in different
forms such as charts by using a
scientific approach for easy
understanding

Key Benefit for Stakeholders from this report
The study provides an in-depth analysis of the Canada Dermatology Prescription Market with current trends and future
estimations to elucidate the imminent investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2021 to 2030 is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

Canada Dermatology Prescription Market Analysis :
Market Overview

Glance at Canada Dermatology Market
GROWTH
RATE
SKIN
DISEASE
KEY
DRIVERS
RETAIL
DRUG
STORES
The Canada Dermatology
Prescriptions Market is likely
to record a considerable
growth rate in the coming
years
Increasing cases of skin diseases like
psoriasis, acne, rosacea, Eczema,
Actinic Keratoses are the key
growth factors for driving
Dermatology Prescription market in
Canada
Increasing partnership with
academia, small and medium
sized enterprises, government
and research centers as well as
contract research organizations
are also acting as key driving
factors
Accessibility of retail drug stores
and hospitals are also
contributing to the growth of the
Prescription Drug market in
Canada

Canada Dermatology Prescription Market Analysis (Current and Forecast)
 Canada Dermatology Prescription market size stood at
around USD 459.7 million in 2022 and is projected to reach
USD 927.4 million by 2030, exhibiting a CAGR of around
9.2% during the forecast period
 Increasing cases of skin diseases, investments of various
companies in skin diseases treatment, increasing geriatric
population looking for solutions to maintaining healthy skin
are the factors driving market for Dermatology Prescription
 Technological advancements and the strong pipeline of
drugs are also anticipated to fuel the growth of the market in
the future in Canada
424.1
459.7
499.1
542.7
591.1
644.9
704.6
771.0
845.0
927.4
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Canada Dermatology Market Size (US$ Mn) 2021-2030F Key Analysis

Growth Drivers and Growth Restraints

Market Growth Drivers
Growing Burden of Skin
Diseases
Increase in approval of
Dermatology drugs
Increase in the geriatric
population
Increase in public health care
spending in Canada

 In Canada, 20% of the population has acne issues, around 1
million are diagnosed with psoriasis, 2 million Canadians have
rosacea
 In 2019, an estimated 7,800 Canadians were suffering with
melanoma. Among youth and adults , melanoma was 5th most
common newly diagnosed cancer
 As per Eczema Society of Canada, Atopic dermatitis, the most
common form of eczema, is a common skin condition, and is
estimated to impact around 10-15% of Canadians
 As per the World Cancer Research fund, In 2020, Canada’s
Non-melanoma skin cancer number was around 61,645. Also,
In 2021, the number of cases of Lyme disease which is a skin
disease was reported to be more than 950 in Canada
 Thus, Canada’s Dermatology market is majorly driven by the
rising burden of Skin diseases in the region
Prevalence of Skin Diseases in 2020
1. Growing Burden of Skin Diseases
7,800 61,645 950
2,000,000
1,000,000
Melanoma Non-melanoma
skin cancer
Lyme disease Rosacea Psoriasis

 The population of seniors in Canada, those aged 65 and more,
is predicted to increase by 68 percent during the next 20 years.
It has more than tripled in size in the last 40 years
 The senior population increased from around 2 million to 3.5
million between 1977 and 1997. In 2017, the population was
around 6.2 million
 In comparison to the general seniors population, the older
seniors population, defined as those aged 75 and up, is rising at
a higher rate. Furthermore, it is expected that the number of
people aged 75 and up in Canada would double in the coming
years
 Geriatric population is more prone to suffer from skin diseases
as compared to young people, which ultimately boosts the
growth of the Canadian dermatology market
Population of people above 65+
2. Increase in the geriatric population
2
3.5
6.2
10.4
1977 1997 2017 2037
Population in Million

 Increase in approvals of new drugs by Health Canada in
treatment of various skin disease is driving Canada
Dermatology Prescription Market.
• In 2019, Health Canada approved Skyrizi for adults with
moderate to severe plaque psoriasis who are candidates
for systemic therapy or phototherapy.
• In 2020, Dupixent was approved in Canada to treat for
moderate-to-severe atopic dermatitis in adults and
adolescents.
• In 2022, Health Canada approved Bimzelx for the
Treatment of Adults with Moderate to Severe Plaque
Psoriasis.
 Thus, Canada’s Prescription Dermatology market is driven by
the Increase in approval of Dermatology drugs in the region.
Number of Biosimilars Approved
3. Increase in approval of Dermatology drugs
3
9
3
9
2016 2020
Total No of Biologics
Total no of Dermatological Biologics

 Total public health care spending in Canada was $265 billion in
2019, which represented 11.5% of the country’s gross domestic
product
 Public spending on prescription drugs accounted for 6% of
national public health care expenditures which was $15.9
billion
 Increase in public spending also resulted in the increase in total
prescription purchase in Canada
• For instance, In 2020, total prescription purchases in
Canada grew 4.3% from the previous year, reaching $32.7
billion compared with $31.4 billion in 2019
 Thus, Canada’s Prescription Dermatology market is driven by
the Increase in Increase in public health care spending in the
region
Spending on Healthcare and prescription drugs
4. Increase in public health care spending
265.0
15.9
health care prescription drugs
Spending in US$ Billion

Market Restraints
Availability of alternative
treatments
Side effects associated with
dermatology drugs
 The medications which are
administered by the patients for treating
skin diseases may possess certain side
effects
 For instance, Around 24% Patients are
experiencing side effects/adverse
events with Moderate/severe atopic
dermatitis, which interfere with their
willingness to take their medication. For
those with moderate/severe atopic
dermatitis, spider veins was most
common side effect (47%), followed by
thinning of the skin and headaches
High cost of dermatology drugs and
treatment
 Cost of Biologic medications like
Infliximab is around US$ 415.1,
Etanercept is US$ 201.1 for psoriasis
treatment
 The monthly cost for medication like oral
corticosteroid is 11-50 US$, Methotrexate
is 20-21US$, Topical corticosteroid is 1-
200US$
 Also, The annual cost per patient was
more than US$282 for those with mild
atopic dermatitis, more than US$454 for
moderate atopic dermatitis, and
US$1,242 for severe atopic dermatitis,
costing approximately US$4.1 billion to
Canada’s healthcare system
 Alternative Treatments such as
Ultraviolet light A or B phototherapy,
Alternative medicines like acupuncture,
Natural or herbal remedies, Skin
washing with antiseptic remedies may
act as an alternative to the prescription
dermatology drugs
 Thus, Availability of alternative
treatments act as a significant restraint
to the Dermatology prescription drug
market in Canada

Canada Dermatology Market Analysis:
Major Dermatological Diseases

Alopecia
 Alopecia refers to hair loss on the body
and scalp
 In Canada, the annual years of healthy
life lost per 100,000 people from
Alopecia Areata has increased by
10.7% and an average of 0.5% a year
Atopic Dermatitis
 Atopic Dermatitis (AD) is hereditary
and the most common type of eczema
 Up to 17% of Canadians suffer from AD at
some point in their lives
 AD almost starts in infancy or before age 5
Psoriasis
 Psoriasis affects around 1 million
Canadians
 Most common form is plaque psoriasis,
which affects approximately 90% of
patients
 Up to 30% of patients with psoriasis
have or will have arthritis
Rosacea
 Around 1.5 to 2 million Canadians
have rosacea
 People between the ages of 30 and
60 years are most typically affected
 Rosacea is most common in women
and people with fair skin
Major
Dermatological
Diseases

Keratinocyte Carcinomas
 Keratinocyte carcinoma (KC) also
called as nonmelanoma skin cancer
 Keratinocyte Carcinomas is estimated
to cause total 201,302 cases in
Canada with over 600 deaths
Melanoma
 In 2019 an estimated 7,800 Canadians
were diagnosed with melanoma and
1,300 died from it
 Melanoma accounts for about 3.8% of
new cancer cases and is one of the
major cause of death
Hyperhidrosis
 Hyperhidrosis is a disorder
that defines individuals who
sweat more than the body
would normally need to
maintain optimal
temperature
 Hyperhidrosis affects
approximately 3% of the
Canadian population
 Out of 950,000 Canadians
suffering from
Hyperhidrosis, about
300,000 have a severe form
of the disorder
Major
Dermatological
Diseases

Market Segmentation

31
31 A Sample Report on Canada Dermatology Market I Confidential
Snapshot of Dermatology Market Segmentation
DISEASE TYPE
DRUG CLASS
ROUTE OF
ADMINISTRATION
END USERS
DISTRIBUTION CHANNEL

32
32 A Sample Report on Canada Dermatology Market I Confidential
Snapshot of Dermatology Market Segmentation
DISEASE TYPE DRUG CLASS
ROUTE OF
ADMINISTRATION END USERS
DISTRIBUTION
CHANNEL
• Acne
• Dermatitis
• Psoriasis
• Skin Cancer
• Alopecia
• Rosacea
• Anti-infectives
• Corticosteroids
• Calcineurin
inhibitors
• Retinoids
• Antirheumatic
• Oral
• Topical
• Parenternal
Administration
• Home Care
• Hospital
• Dermatology
Clinics
• Pharmacy
Store
• Retail Store
• Online
• Supermarkets

Market Segmentation: By Disease Type
Acne
4.7%
Dermatitis
9.9%
Psoriasis
29.1%
Skin Cancer
39.2%
Rosacea
6.6%
Others
10.5%
19.9
42.0
123.4
166.2
28.0
44.5
Acne Dermatitis Psoriasis Skin Cancer Rosacea Others
 Canada Dermatology Prescription market was valued at US$ 424.1 Mn in 2021. Skin Cancer segment for Canada Dermatology Prescription market was valued at
US$ 166.2 million, and possess largest share in the Disease Type segment. The segment is expected to grow at a CAGR of 9.5% during the forecast period
• For instance, There were more than 7,800 cases of Melanoma in Canada, and rate is estimated to grow in future years
 The market revenue for the Psoriasis segment was around US$ 123.4 million in 2021 due to increasing cases of Psoriasis in Canada. As per Canadian Psoriasis
Network, one million Canadians are affected by psoriasis
Key highlights
Canada Dermatology Prescription Market Revenue by Disease Type
2021 (US$ Mn)
Canada Dermatology Prescription Market Share by Disease Type
2021

Market Segmentation: By Drug Class
Monoclonal
antibodies
55.3%
Corticosteroids
12.6%
Retinoids
7.1%
Antibiotics agent
9.9%
Antifungal
Agents
8.4%
Others
6.7%
234.5
53.4
30.1
42.0 35.6 28.4
Monoclonal
antibodies
Corticosteroids Retinoids Antibiotics agent Antifungal
Agents
Others
 The Monoclonal antibodies segment for Canada Dermatology Prescription market was valued at US$ 234.5 million in 2021 and is projected to reach US$ 531.4 million
by 2030. Monoclonal antibodies segment is expected to grow at a CAGR of 9.6% during the forecast period
• By the end of 2020, Health Canada had approved 9 biosimilars indicated to be used in Psoriasis
 The market revenue for the Corticosteroid segment was around US$ 53.4 million in 2021. Increasing use of Corticosteroid in treating skin diseases such as dermatitis,
eczema is boosting growth of this segment
Key highlights
Canada Dermatology Prescription Market Revenue by Drug Class
2021(US$ Mn)
Canada Dermatology Prescription Market Share by Drug Class 2021

Market Segmentation: By Route of Administration
Parenteral
55.3%
Topical
16.3%
Oral
28.4%
234.5
69.1
120.4
Parentral Topical Oral
 The Parenteral segment for Canada Dermatology Prescription market was valued at US$ 234.5 million in 2021, and is projected to reach US$ 531.4 million by 2030.
Parenteral segment is expected to grow at a CAGR of 9.6% during the forecast period
• Increasing use of biologics in various skin disease treatment which are administered by infusion route, or transdermal route boosts segments growth
 The market revenue for the Oral segment was around US$ 120.4 million in 2021. Increasing cases of skin diseases in Canada, and increasing use of oral drugs such
as antibiotics for their treatment is boosting growth of Oral segment
Key highlights
Canada Dermatology Prescription Market Revenue by Route of Administration
2021(US$ Mn)
Canada Dermatology Prescription Market Share by Route of Administration
2021

Market Segmentation: By Distribution Channel
Retail Pharmacy
79.2%
Hospital
Pharmacy
18.2%
Online Pharmacy
2.6%
335.9
77.2
11.0
Retail Pharmacy Hospital Pharmacy Online Pharmacy
 The Retail Pharmacy segment for Canada Dermatology Prescription market was valued at US$ 335.9 million in 2021 and is projected to reach US$ 731.7 million in
2030. Retail Pharmacy segment is expected to grow at a CAGR of 9.1% during the forecast period
• For instance, Retail purchases in 2020 increased by 3.8% from 2019 in Canada due to increasing cases of diseases
 The market revenue for the Hospital Pharmacy segment was around US$ 77.2 million in 2021. According to Canadian Trends and Projections, Hospital purchases in
2020 increased by 6.9% from 2019 in Canada
Key highlights
Canada Dermatology Prescription Market Revenue by Distribution Channel
2021(US$ Mn)
Canada Dermatology Prescription Market Share by Distribution Channel
2021

Prescription Major Products Market Share

Major Dermatology Prescription Products Market Share
 In 2021, The Monoclonal antibodies segment accounted for 55.3% market share, and was valued at 234.5 Mn in the total Dermatology Prescription Products Market.
Biologics like Remicade, Humira , Stelara, Enbrel, Keytruda which are used in skin conditions such as Psoriasis and Melanoma constituted strong share in market
• For instance, in 2018, Remicade generated sales revenue of around $1,081 Million in Canada. Humira generated sales revenue of around $800 Million, Stelara
generated sales revenue of around $338 Million, Enbrel generated sales revenue of around $291 Million, Keytruda generated sales revenue of around $202
Million
 The market share for the Corticosteroid segment was around 12.6%, and was valued at 53.4 Mn in 2021. Corticosteroids are largely used in treatment of skin diseases
such as dermatitis, eczema, psoriasis etc.
Canada Dermatology Prescriptions Products Market Share Analysis (US$ Mn)
234.5
255.2
278.2
303.7
332.1
363.8
53.4 58.1 63.2 68.9 75.3 82.3
30.1 32.5 35.2 38.2 41.4 45.1
42.0 45.5 49.3 53.5 58.3 63.5
35.6 38.5 41.7 45.2 49.1 53.5
28.4 29.9 31.4 33.1 34.9 36.8
2021 2022F 2023F 2024F 2025F 2026F
Monoclonal antibodies Corticosteroids Retinoids
Antibiotics agent Antifungal Agents Others

Notable deals in the recent years in the
Canada Dermatology prescription Market
Distribution
Partnership
Product Launch
Acquisition
March, 2022, Sun Pharma acquired Galderma
companies in US, Japan & Canada. Galderma
specializes in skin related disorders and has a
major presence in U.S. and Canada
September 2021, Crescita entered into an
exclusive Canadian Distribution Agreement with
Obagi Cosmeceuticals LLC. Crescita
Therapeutics is a commercial dermatology
company with a portfolio of prescription and
non-prescription products for the treatment and
care of skin conditions.
March 2022, Miravo Healthcare, a Canadian-
focused healthcare company launched Blexten
for the treatment of hives and itching of chronic
spontaneous urticaria.

Competitive Landscape

Competitive landscape: Key players analysis
Analysis
Canada Dermatology Prescription Market Players
 Leading Players:
 Johnson and Johnson Company
 Merck & Co., Inc.
 Pfizer Inc.
 Roche
 Prominent Players:
 Bayer
 Glaxo SmithKline Company
 Novartis
 Astra Zeneca
 Emerging players:
 Taro Pharmaceutical
 Bausch Health
Emerging players
3,812
621 324
324
349
1,394
286
Prominent
Players
leading
Players

Key Company Profiles

Major Players

Company profile
 Glaxo SmithKline Company currently employ approximately
2,600 full time employees across Canada
 Glaxo SmithKline Company have two divisional headquarters in
Mississauga, Ontario and Montréal, Quebec, and an
administrative office in Quebec City
 Manufacturing facilities of GSK in Canada are located in Ste-
Foy, Quebec, and Ville Saint-Laurent, Quebec
 Glaxo SmithKline subsidiary Stiefel deals with dermatology
products of GSK, which include an combined portfolio of daily
skin care and prescription treatments
 Examples of some of the Stiefel’s dermatology Products, which
are marketed in Canada includes Clindoxyl, Stieprox , Stieva-
A, Toctino
 Glaxo SmithKline turnover in Dermatology segment for year
2021 was 518 Million US$ globally
Company Name: Glaxo
SmithKline Company
Year of Establishment: 1830
Headquarter: Middlesex, England
Revenue: $44,725 Million (2021)
website: www.ca.gsk.com
1. Glaxo SmithKline Company

Company profile
 Johnson & Johnson is one of the largest and most broadly
based healthcare company in the world
 Johnson & Johnson is organized into three business segments,
namely Consumer, Pharmaceutical, and Medical Devices
 Johnson & Johnson Pharmaceutical segment is focused on six
therapeutic areas, namely immunology, oncology, infectious
diseases, neuroscience, cardiovascular and metabolism, and
pulmonary hypertension
 Johnson & Johnson products Stelara, and Tremfya indicated
for the use in Plaque Psoriasis are approved by Health Canada
 In 2019, Stelara sales in Canada was reported to be around
US$ 295.4 Million
Company Name: Johnson &
Johnson Company
Headquarter: New Jersey, United States
website: www.jnjcanada.com
2. Johnson and Johnson Company

Company profile
 Merck & Co., an American affiliate, develops and manufactures
pharmaceuticals, vaccines, biologic therapies, and animal
health products
 Merck Inc operates under Healthcare, Life Science, and
Performance Materials Business segments
 Merck Inc has approximately 74,000 total employees across all
of its locations and generates $20,498 million in sales
 Merck Inc. subsidiary in Canada, Merck Canada Inc is located in
Kirkland, Canada, and consists of diversified portfolio of
prescription medicines, vaccines and animal health products
 Merck’s Canada dermatology based prescription products
include Cubicin, Cubicin rf, Sivextro, Hadlima, Keytruda, etc.
 Keytruda’s sales revenue in Canada increased from $206.3
million in 2018 to 280.4 Million in 2019
Company Name: Merck & Co.,
Inc.
Headquarter: New Jersey, United States
website: www.merck.ca
3. Merck

Company profile
 Pfizer Inc. is a biopharmaceutical company that discovers,
develops, manufactures, and sells healthcare products globally,
and primarily focus on the R&D of biosimilars, inflammation and
immunology, metabolic diseases and cardiovascular risks,
neuroscience, oncology, rare diseases, and vaccines
 Pfizer Inc. operates through the Global Innovative
Pharmaceutical (GIP), Global Vaccines, Oncology, and
Consumer Healthcare (VOC), and Global Established
Pharmaceutical (GEP) segments
 Pfizer Canadian Locations includes Montreal, Quebac, and
Brandon, Monitoba, which are manufacturing facilities for Pfizer
 Pfizer Canada dermatology based prescription products include
Eucrisa, Dalvance, Cibinqo, etc.
Company Name: Pfizer Inc.
Headquarter: New York, United States
website: www.pfizer.ca
4. Pfizer

Company profile
 Novartis AG is a global pharmaceutical company consisting of
two business operating divisions: Innovative Medicines and
Sandoz (generics)
 Novartis provides ophthalmology, neuroscience, immunology,
hepatology and dermatology, respiratory, cardio-metabolic, and
established medicine products. The company offers an
extensive platform and technology for cell and gene therapy
 Novartis Pharmaceuticals Canada Inc., is the Novartis AG
subsidiary in Canada, and is located in Dorval, Quebec
 Novartis Canada dermatology based prescription products
include Cosentyx, Xolair, etc.
Company Name: Novartis AG
Headquarter: Basel, Switzerland
website: www.novartis.ca
5. Novartis

Company profile
 AstraZeneca focuses on the discovery, development, and
commercialization of prescription medications in oncology and
biopharmaceuticals, including cardiovascular, renal, and
metabolic diseases, as well as respiratory and immunological
diseases
 Astra Zeneca’s subsidiary in Canada, Astra Zeneca Canada,
employs roughly 900 people in Canada in research to develop
and market innovative medicines. AstraZeneca Canada was
recently designated a global Clinical Hub for oncology and
immuno-oncology clinical studies, and they are currently leading
global oncology clinical studies in lung, head and neck cancer
 Astra Zeneca Canada’s major dermatology prescription product
is Siliq, which used to treat moderate to severe plaque psoriasis
in adults
Company Name: Astra Zeneca
Headquarter: Cambridge, United Kingdom
website: www.astrazeneca.ca
6. Astra Zeneca

Company profile
 Bayer AG has been involved in the development, manufacture,
and distribution of products in areas of healthcare, nutrition, and
high-tech materials
 The company operates through three segments:
Pharmaceuticals, Consumer Health, Crop Science segments
 The Pharmaceuticals segment engages in the development,
production, and marketing of prescription products for
cardiology and women's healthcare, specialty therapeutics in
the areas of oncology, hematology, ophthalmology, diagnostic
imaging equipment, and the necessary contrast agents
 Bayer Canada dermatology based prescription products include
finacea, Tinactin, Ciproxl, etc.
Company Name: Bayer AG
Headquarter: Leverkusen, Germany
website: https://www.bayer.com/en/ca/canada-
home
7. Bayer

Company profile
 Roche Holding AG are a global leader in biopharmaceuticals,
and in vitro diagnostics sectors, and are an innovator across
major disease areas
 Roche Holding AG operates through the two segments, namely
Roche Pharmaceuticals, and Roche Diagnostics
 Roche Canada is the Roche Holding AG subsidiary in Canada,
which employees around 1,800 people across the Canada
through its Pharmaceuticals division in Mississauga, Ontario
and Diagnostics, as well as Diabetes Care divisions in Laval,
Quebec
 In 2019, Roche prescription product Rituxan, which is also used
to treat psoriasis reported sales of around US$ 261.2 Million in
Canada
Company Name: Roche
Holding AG
Headquarter: Basel, Switzerland
website: www.rochecanada.com
8. Roche

Company profile
 Taro Canada is the subsidiary of Taro Pharmaceutical Industries
Ltd in Canada, which manufactures more than 200 finished
dosage form pharmaceutical products for sale in Canada and
for export to the U.S. and other markets. It also Markets and
distributes both proprietary and generic products in the
Canadian market
 Taro Canada Primary Product Lines includes, Dermatology: Rx
and OTC semi-solid products (creams, ointments, lotions and
gels) and liquid products, Allergy (Antihistamine): OTC oral
dosage products
 Taro Pharmaceutical Industries Ltd. Product portfolio in the
Dermatology category includes, Zyclara, Cloderm, Sklice,
Sinequan, Fioricet, Taclonex, Bactroban, Sernivo, Cleocin T,
Clobex, etc.
Company Name: Taro
Pharmaceutical Industries Ltd.
Headquarter: New York, United States
Revenue: $548.97 Million (2021)
website: www.taro.com
9. Taro Pharmaceutical

Healthcare Policy and Regulatory Landscape

Canadian Healthcare Policy
Federal government provides drug
coverage for selected populations
(e.g., eligible First Nations people),
which account for 2% of prescription
drug expenditure in Canada
Canada has a public
funded health scheme,
known as “Medicare:”,
which provides
comprehensive coverage
Provincial governments
currently finance between
28% and 41% of
prescription drug
expenditure in their
jurisdictions through public
drug plans
22% of prescription drug spending
in Canada is financed out-of-pocket
by patients because approximately
11% of Canadians have no
prescription drug coverage
In 2018 , Canada
Health Infoway
launched ACCESSS
2022 an initiative that is
intended to expand the
access of Canadians to
their health information

Drug regulatory and reimbursement in Canada
HEALTH CANADA
Patented Medicine Prices Review Board (PMPRB)
Must be notified of drug price at first sale in Canada
Canadian Agency for Drugs &
Technologies in Health ( CADTH) Common
Drug Review ( CDR)
Pan- Canadian Oncology Drug Review
pCODR
Quebec –INESSS Private Insurers
Pan- Canadian Pharmaceutical Alliance (pCPA)
Provincial Drug Plans
Formulator listing at the discretion of the drug plans
Employers
Patients covered by Drug Plan
Cash Paying Patients approximately
10% of Rx’s

Future Outlook

Opportunities for future growth
1
2
3
5
4
Increasing Demand
Growing demand of
dermatology prescription
drugs at Hospital
Pharmacies, and Retail
Pharmacies to drive the
growth of market future
Initiatives to increase
Awareness
Increase in launches of
awareness campaign to learn
about self-skin examinations
will create ample
opportunities in the market
New Opportunities
New innovations in Dermatology
technologies, research and trials
are going to increase the scope
of Dermatology prescription
products in future
Government funding and
Reimbursement
Increase in funding by
Government of Canada more
on the healthcare services in
future may increase the
scope of Reimbursement
New Developments
Manufacturing companies in
Canada are already leveraging
on the government support to
the healthcare R&D. This support
may bring high developments in
future for Dermatology
Prescription market

Canada Dermatology prescription Market

Recommended

Recommended

More Related Content

Similar to Canada Dermatology prescription Market

Similar to Canada Dermatology prescription Market (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Canada Dermatology prescription Market